Want to see SCYX full AI Analyst Report?
Top Page
SCYNEXIS
(NASDAQ:SCYX)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.00
▼(-29.45% Downside)
Action:Reiterated
Date:10/02/26
The score is held back primarily by weak financial performance (TTM losses, negative margins, and ongoing cash burn) and a negative P/E that reflects lack of current profitability. Offsetting factors include supportive corporate events—especially the potential non-dilutive BARDA funding—and moderately improving near-term technicals, though the longer-term trend remains below the 200-day moving average.
Positive Factors
Non-dilutive development funding
The BARDA cost-share contract can fund substantial eligible development and administrative costs without immediate equity dilution. Its support for SCY-247 and SCY-770 through Phase 2 may extend financial flexibility, preserve the stated cash runway, and advance the antifungal pipeline.
Negative Factors
Persistent unprofitability
Deeply negative net, EBIT, and EBITDA margins show that current operations are not yet economically self-sustaining. Unless commercialization or licensing economics improve materially, ongoing losses can consume equity, constrain reinvestment, and make durable earnings generation difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive development funding
The BARDA cost-share contract can fund substantial eligible development and administrative costs without immediate equity dilution. Its support for SCY-247 and SCY-770 through Phase 2 may extend financial flexibility, preserve the stated cash runway, and advance the antifungal pipeline.
Read all positive factors
SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.66M
Dividend YieldN/A
Average Volume (3M)395.73K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth489.78%
EPS Growth45.39%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume73,308
30 Day Avg. Volume395,729
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap-0.11
Enterprise Value/Revenue-0.21
Enterprise Value/Gross Profit-0.21
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$32.00Price Target Upside464.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$619.50K
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive ...
How the Company Makes Money
SCYNEXIS generates revenue primarily through the commercialization and licensing of its antifungal drug assets, most notably ibrexafungerp. The company’s revenue model may include: (1) product sales in markets where it (or a commercial partner) ha...
SCYNEXIS Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 19.21M | 20.60M | 3.75M | 140.14M | 5.09M | 13.16M |
| Gross Profit | 19.21M | 20.60M | 3.75M | 124.52M | 4.46M | 12.85M |
| EBITDA | -10.23M | -8.12M | -18.58M | 70.89M | -60.12M | -32.91M |
| Net Income | -10.23M | -8.61M | -21.29M | 67.04M | -62.81M | -32.87M |
Balance Sheet | ||||||
| Total Assets | 74.97M | 59.03M | 90.64M | 128.41M | 87.81M | 119.84M |
| Cash, Cash Equivalents and Short-Term Investments | 54.08M | 21.26M | 59.30M | 74.36M | 73.50M | 104.48M |
| Total Debt | 1.95M | 2.17M | 16.27M | 15.08M | 48.60M | 43.63M |
| Total Liabilities | 8.04M | 9.65M | 35.57M | 55.45M | 84.58M | 78.58M |
| Stockholders Equity | 66.93M | 49.38M | 55.08M | 72.96M | 3.23M | 41.26M |
Cash Flow | ||||||
| Free Cash Flow | -13.31M | -5.28M | -24.01M | 60.16M | -79.89M | -55.73M |
| Operating Cash Flow | -13.31M | -5.28M | -24.01M | 60.16M | -79.88M | -54.56M |
| Investing Cash Flow | -24.69M | 24.31M | 6.15M | -34.88M | -27.39M | -1.17M |
| Financing Cash Flow | 37.41M | -14.17M | -139.00K | -36.72M | 48.60M | 67.12M |
SCYNEXIS Technical Analysis
Negative
5.67
Price Trends
4.69
Negative
4.53
Negative
5.58
Negative
Market Momentum
-0.28
Positive
35.94
Neutral
41.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 5.67 is above the 20-day moving average (MA) of 4.30, above the 50-day MA of 4.69, and above the 200-day MA of 5.58, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 35.94 is Neutral, neither overbought nor oversold. The STOCH value of 41.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $27.97M | -4.99 | -14.03% | ― | -21.12% | -109.07% | |
56 Neutral | $127.21M | -11.88 | -47.10% | 16.33% | -25.68% | -244.92% | |
55 Neutral | $20.83M | -95.74 | -0.80% | ― | 27.78% | 52.88% | |
54 Neutral | $20.65M | -1.39 | -52.89% | ― | -13.27% | 27.11% | |
52 Neutral | $37.66M | -2.06 | -21.10% | ― | 489.78% | 45.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
38 Underperform | $1.45M | -0.04 | 841.81% | ― | -11.91% | -285.26% |
* Healthcare Sector Average
SCYX
SCYNEXIS
3.79
-2.24
-37.17%
RMTI
Rockwell Med
6.94
-4.46
-39.12%
TXMD
TherapeuticsMD
1.80
0.49
37.40%
AYTU
Aytu BioScience
1.90
-0.31
-14.03%
CPIX
Cumberland Pharmaceuticals
8.49
6.02
243.31%
IMCC
IM Cannabis Corp
0.88
-42.02
-97.96%
SCYNEXIS Corporate Events
Business Operations and StrategyPrivate Placements and Financing
SCYNEXIS Secures BARDA Funding for Antifungal Pipeline
Positive
Sep 28, 2026
On September 25, 2026, SCYNEXIS entered into a cost-share contract with the U.S. Biomedical Advanced Research and Development Authority that provides up to $214 million in potential non-dilutive funding to support SCY-247, its second-generation fu...
Business Operations and StrategyExecutive/Board Changes
SCYNEXIS adds veteran biopharma leader to board
Positive
Sep 22, 2026
On September 18, 2026, SCYNEXIS appointed seasoned biopharmaceutical executive Steven K. Burke, M.D., to its Board of Directors and to the Nominating and Corporate Governance Committee, formalizing the move in a press release issued on September 2...
Business Operations and StrategyExecutive/Board Changes
SCYNEXIS appoints new CFO amid leadership transition
Positive
Sep 10, 2026
On September 9, 2026, SCYNEXIS Chief Financial Officer Ivor Macleod retired from his roles as principal financial and accounting officer, with his employment to conclude on October 9, 2026 after a transition period. The company simultaneously move...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.